VET-T 0.05 AMD-Q -3.42 AEM-T -1.41 IMO-T 0.34 AEM-T -1.41 MGRC-Q -2.865
Daily Stock Opinions and Ratings

Latest Stock Buy or Sell? Make More Informed Decisions!

Today, Gordon Reid and Jim Cramer - Mad Money commented about whether FANG-Q, ET-N, CWEN-Q, LVS-N, PLTR-Q, NRZ-N, STWD-N, IRM-N, IIPR-N, VTR-N, EQIX-Q, PLD-N, SKT-N, SPG-N, CCI-N, AMT-N, BLDR-Q, CMG-N, MRVL-Q, BYND-Q, DELL-N, DRI-N, NKE-N, COST-Q, WDAY-Q, ADBE-Q, FDX-N, LEN-N, JNJ-N, PFE-N, BX-N, AMZN-Q, RTX-N, GS-N, INTC-Q, MRNA-Q, MA-N, BHP-N, QCOM-Q, MSFT-Q, AAPL-Q, PAYX-Q, EW-N, WM-N, MDLZ-Q, HXL-N, ABBV-N, JPM-N, GOOG-Q, FCX-N are stocks to buy or sell.

  • Next Page
DON'T BUY

Mastercard Inc.(MA-N)

Sep 17, 2021
They do not take any credit risk. They are a transaction company, and with the move away from cash, MA will benefit. However, the valuation compared to their historic multiple is high. They used to trade at a market multiple. Now, it is at 2x the market multiple. It has been rerated. However, thinks it is stretched and any economic dislocation can see a big correction.
Gordon ReidGordon Reid
Unknown
Unlock Rating
$343.040

Stock price when the opinion was issued

other services
DON'T BUY

Moderna(MRNA-Q)

Sep 17, 2021
In the news for their vaccine. It's pretty much all their business right now. Total revenue was $60M, but their market cap is $170B. The question is, are their legs with the vaccine franchise. They have lots of drugs in their pipeline, but there is a lot of risk.
Gordon ReidGordon Reid
No
Unlock Rating
$424.160

Stock price when the opinion was issued

Pharma & Healthcare
DON'T BUY

Intel(INTC-Q)

Sep 17, 2021
Years ago, it was the darling of the chip space. They have fallen on hard times. They still do $75B in business but they cannot get traction from a growth standpoint. Greatest attribute is the cheap valuation around 12x earnings. More a value trap. It could turn itself around. There are other better opportunities.
Gordon ReidGordon Reid
No
Unlock Rating
$54.280

Stock price when the opinion was issued

computer parts mnfctr
BUY

Goldman Sachs(GS-N)

Sep 17, 2021
Capital market business is on fire in the US. There is tremendous amounts of liquidity. Goldman has been successful in this business. Chosen to go with other opportunities with banking, loan spreads, but still likes this.
Gordon ReidGordon Reid
No
Unlock Rating
$391.460

Stock price when the opinion was issued

investment companies funds
BUY

Raytheon(RTX-N)

Sep 17, 2021
Likes it. An aerospace company in defence. The aerospace part has not been doing well, but it is starting to get legs. The combined operation is still undervalued. They spin off a lot of cash. Should support growth in their capital allocation policy leading to higher dividends and stock buybacks.
Gordon ReidGordon Reid
Owned
Unlock Rating
$83.390

Stock price when the opinion was issued

Defense
BUY

Amazon.com, Inc.(AMZN-Q)

Sep 17, 2021
Can buy now. A fairly recent entry to his portfolio. Always a mystery from a financial standpoint. Becoming more traditional in their accounting and how they allocate capital. New CEO that is investing heavily in distributions and fulfillment centres. More same day delivery is coming. Cloud business is the best in the world too. Getting involved with content and bought MGM now. A company that is growing quickly.
Gordon ReidGordon Reid
Owned
Unlock Rating
$3461.790

Stock price when the opinion was issued

specialty stores
BUY

Blackstone Group LP(BX-N)

Sep 17, 2021
A public vehicle in the quasi-private business. Takes advantage of opportunities in the marketplace, hold them until they mature, and then sells them. They continue churning money. Incredibly successful at it. Can continue to hold the company. They pay out a percentage of their profit bases. Switched from a LP to a regular listed company. Continues to pay fairly large distributions.
Gordon ReidGordon Reid
No
Unlock Rating
$133.730

Stock price when the opinion was issued

investment companies funds
DON'T BUY

Pfizer Inc(PFE-N)

Sep 17, 2021
A broad company with many types of drugs. Laws in the US stipulates that after spending millions of dollar for franchises, the drug will go off patent in time. Pharmaceuticals have been doing this for a long time.
Gordon ReidGordon Reid
No
Unlock Rating
$43.890

Stock price when the opinion was issued

biotechnology pharmaceutical
DON'T BUY

Johnson & Johnson(JNJ-N)

Sep 17, 2021
Broadly, pharmaceuticals and healthcare space is not providing a ton of opportunity. Trading at reasonable valuations with 3 divisions. Consumer business is in trouble because more people are going towards generics. Pharma business hasn't seen much tailwind from covid vaccines.
Gordon ReidGordon Reid
No
Unlock Rating
$164.750

Stock price when the opinion was issued

biotechnology pharmaceutical
COMMENT

A Comment -- General Comments From an Expert(A Commentary)

Sep 17, 2021
He's been saying that the seasonal period starting today will be a rocky one. It was as stocks sank today. Also, bearish sentiment hasn't peaked since the Dotcom period. Also stocks pull back, you may need to buy into that decline. September/October seasonality is consistent. This year, supply chain constraints, the Delta effect and other worries are factors.
Jim Cramer - Mad MoneyJim Cramer - Mad Money
Unknown
Unlock Rating
COMMENT

Lennar Corp.(LEN-N)

Sep 17, 2021
They report Monday. Excellent managers. He wants them to talk about supply shortages and home demand. Lennar is important to retail, banking and the hybrid work from home economy.
Jim Cramer - Mad MoneyJim Cramer - Mad Money
Unknown
Unlock Rating
$101.280

Stock price when the opinion was issued

REAL ESTATE
COMMENT

FedEx(FDX-N)

Sep 17, 2021
It reports Tuesday. It has been hit with a ton of negative commentary. Will they say anything to give us a reason to buy? We'll see.
Jim Cramer - Mad MoneyJim Cramer - Mad Money
Unknown
Unlock Rating
$255.220

Stock price when the opinion was issued

Transportation
BUY

Adobe Systems(ADBE-Q)

Sep 17, 2021
It reports Tuesday. It's become the bellwhether of tech stocks. The stock has been on fire, because business is booming; their products are essential to e-commerce. He loves their suite of products.
Jim Cramer - Mad MoneyJim Cramer - Mad Money
Unknown
Unlock Rating
$654.810

Stock price when the opinion was issued

computer software processing
BUY ON WEAKNESS

Workday(WDAY-Q)

Sep 17, 2021
It reports Tuesday. Their last quarter was good. If shares got hammered Monday and Tuesday, maybe you can buy this lower on Wednesday.
Jim Cramer - Mad MoneyJim Cramer - Mad Money
Unknown
Unlock Rating
$268.510

Stock price when the opinion was issued

0
BUY ON WEAKNESS

Costco Wholesale Corporation(COST-Q)

Sep 17, 2021
It reports Thursday. He doesn't expect good things. True, the stock has been rallying up in a straight line, but the clueless always expect an upside surprise, then sell it when numbers are merely in-line. A great company. He expects the clueless to sell it.
Jim Cramer - Mad MoneyJim Cramer - Mad Money
Unknown
Unlock Rating
$459.510

Stock price when the opinion was issued

department stores

Build your watch list

Sign in to track investments
you care about

Latest Buy Signals

FCX-N 0.34$44.8
VZ-N -0.11$40.84
META-Q 2.87$704.28
DIS-N -0.79$121.42
AXP-N -7.4$307.95

Today's Top Picks

VET-T 0.05$10.83
AMD-Q -3.42$156.99
AEM-T -1.41$161.61
IMO-T 0.34$112.97
AEM-T -1.41$161.61

Popular Articles

Latest Sell Signals

PLTR-Q -0.47$153.52
INTC-Q 0.3$23.1
CVX-N -1.34$150.04
SII-T 1.77$103.49
ENB-T 0.3$61.88

Most Recent Experts

Lyle Stein

Lyle Stein

Forvest Global Wealth Management

Jenny Harrington, CEO, Gilman Hill Asset Management

Jenny Harrington, CEO, Gilman Hill Asset Management

Gilman Hill Asset Management

Kevin Simpson

Kevin Simpson

Capital Wealth Planning

David Burrows

David Burrows

Barometer Capital Management

The Panic-Proof Portfolio (Stockchase Research)

The Panic-Proof Portfolio (Stockchase Research)

Stockchase Premium

disclaimer

Stockchase, in its reporting on what has been discussed by individuals on business television programs (in particular Business News Network), neither recommends nor promotes any investment strategies.

We paraphrase the experts by hand, we watch the shows and write down what we understood from the experts’ comments. We are human and can make mistakes, help us fix any errors. If you see something that you know is not right or if there is a problem with the site, feel free to email us at: hello@stockchase.com.

About usHow to useContact Us
More...
AdvertisingIn the newsPrivacy PolicyTerms of service
FacebookX
© Stockchase Inc. by Wealthica